Amplitude
  • MAGAZINE
    • Subscribe
    • Current Issue
    • Archives
    • Living With Amplitude
      • Adaptive Living
      • Amputee to Amputee
      • Arts & Culture
      • Education
      • Featured
      • Getting Support
      • Giving Support
      • Health & Medicine
      • Money Matters
      • Relationships
      • Science & Technology
      • Sports & Recreation
      • Transportation & Mobility
      • More Amplitude
  • NEWSLETTER
  • RESOURCES
    • Guide to Living With Limb Loss
    • Prosthetist Search
    • Support Groups
    • Resource Directory
  • ABOUT US
    • Contact Us
    • Advertiser Information
    • Privacy Policy
    • Cookie Policy
    • Cancellation Policy
  • SUBSCRIBE
No Result
View All Result
  • MAGAZINE
    • Subscribe
    • Current Issue
    • Archives
    • Living With Amplitude
      • Adaptive Living
      • Amputee to Amputee
      • Arts & Culture
      • Education
      • Featured
      • Getting Support
      • Giving Support
      • Health & Medicine
      • Money Matters
      • Relationships
      • Science & Technology
      • Sports & Recreation
      • Transportation & Mobility
      • More Amplitude
  • NEWSLETTER
  • RESOURCES
    • Guide to Living With Limb Loss
    • Prosthetist Search
    • Support Groups
    • Resource Directory
  • ABOUT US
    • Contact Us
    • Advertiser Information
    • Privacy Policy
    • Cookie Policy
    • Cancellation Policy
  • SUBSCRIBE
No Result
View All Result
Amplitude

Cancer Drugs: Are They a Good Value?

August 31, 2015
0

At a time when cancer drug prices are rising rapidly, an innovative new study provides the framework for establishing value-based pricing for all new oncology drugs entering the marketplace. Using a highly sophisticated economic model, researchers from Winship Cancer Institute of Emory University and Georgia Institute of Technology used an example of a new lung cancer drug. The study findings were published in JAMA Oncology.

Researchers focused their investigation on a drug called necitumumab, which is awaiting approval from the U.S. Food and Drug Administration. Previous studies have shown that the drug extends the life of patients with metastatic squamous lung cancer by about seven weeks.

The researchers used their economic model to factor medication and administration costs with life expectancy, frequency and management of adverse effects, and quality of life. The results demonstrated that the value-based price for necitumumab ranges between $563 and $1,309 per three-week cycle, which is significantly lower than most cancer drugs that have entered the marketplace recently.

“Cancer drug prices have been skyrocketing in recent years, and these prices are not linked to the benefit that the drugs provide. Most new cancer drugs cost in excess of $10,000 per month,” said lead study author Daniel A. Goldstein, MD. “These rising prices are unsustainable to the system. Potentially life-saving drugs should carry a high price tag, but drugs such as necitumumab that extend life expectancy only by a matter of weeks should cost significantly less.”

According to the study authors, “the current system of paying for cancer drugs in the United States provides little incentive for manufacturers and physicians to consider value when pricing and using drugs.” Although the study determined pricing for one specific drug, the analysis conducted establishes a model by which other cancer drugs can similarly be assessed in the future to develop value-based prices.

The study concludes: “There is currently a crucial step in the drug development and approval process that is missing-an evaluation of cost and value.”

This article was adapted from information provided by Emory Health Sciences.

Tags: educationHealth & MedicineScience & TechnologySpotlight on Books
Previous Post

3D-Printed Robotic Hand Wins UK Dyson Award

Next Post

Healthy Mood Spreads Through Social Contact, Depression Doesn’t

Next Post

Healthy Mood Spreads Through Social Contact, Depression Doesn't


Subscribe Today

Recent Posts

  • Universal Theme Parks Leave Amputees Fuming
  • World Leader in 3D-Printed Sockets Heads to USA
  • ROMP Seeks Volunteers at Amputee Clinics
  • The Amputee Insurance Law You Should Be Tracking Right Now
  • Amputee Caregiver Support, State by State

201 East 4th Street
Loveland, CO 80537
303-255-0843
©2022 Amplitude Media Group

Today’s amputees are living more dynamic lives than ever before. Amplitude Magazine tells their stories.

About Us
Privacy Policy
Subscribe

FOLLOW US

Facebook Twitter Instagram Linkedin

No part of this electronic publication/website may be reproduced in any form or by any means without prior written permission from Amplitude Media Group.

No Result
View All Result
  • MAGAZINE
    • Subscribe
    • Current Issue
    • Archives
    • Living With Amplitude
      • Adaptive Living
      • Amputee to Amputee
      • Arts & Culture
      • Education
      • Featured
      • Getting Support
      • Giving Support
      • Health & Medicine
      • Money Matters
      • Relationships
      • Science & Technology
      • Sports & Recreation
      • Transportation & Mobility
      • More Amplitude
  • NEWSLETTER
  • RESOURCES
    • Guide to Living With Limb Loss
    • Prosthetist Search
    • Support Groups
    • Resource Directory
  • ABOUT US
    • Contact Us
    • Advertiser Information
    • Privacy Policy
    • Cookie Policy
    • Cancellation Policy
  • SUBSCRIBE

Amplitude